Vioxx should be allowed back on the market advises expert panel.
Sibbald
Barbara
B
D002170:Canada; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011307:Drug Prescriptions; D006291:Health Policy; D006801:Humans; D007783:Lactones / Q000009:adverse effects* / Q000627:therapeutic use; D007880:Legislation, Drug; D008389:Marketing of Health Services; D011050:Policy Making; D013450:Sulfones / Q000009:adverse effects* / Q000627:therapeutic use
D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib